Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial.

Autor: Mittal P; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Department of Haematology, Cancer Institute, University College London, London, United Kingdom., Gafoor R; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Sayar Z; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Department of Haematology, Whittington Health NHS Trust, London, United Kingdom., Efthymiou M; Department of Haematology, Cancer Institute, University College London, London, United Kingdom., Tohidi-Esfahani I; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Department of Haematology, Cancer Institute, University College London, London, United Kingdom., Appiah-Cubi S; Department of Haematology, Epsom and St Heliers University Hospitals NHS Trust, Epsom, United Kingdom., Arachchillage DJ; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom., Atkinson D; Centre for Medical Imaging, Division of Medicine, University College London, London, United Kingdom., Bordea E; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Cardoso MJ; Department of Biomedical Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom., Caverly E; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Chandratheva A; Stroke Research Centre, University College London Queen Square Institute of Neurology, London, United Kingdom.; Comprehensive Stroke Service, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Chau M; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Freemantle N; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Gates C; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Ja Ger HR; Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, University College London Institute of Neurology, London, United Kingdom., Kaul A; Department of Rheumatology, St George's Healthcare NHS Trust, London, United Kingdom., Mitchell C; Department of Haematology, North Middlesex University Hospital NHS Trust, London, United Kingdom., Nguyen H; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Packham B; Thrombosis and Anticoagulation service, Royal Free London Hospital NHS Foundation Trust, London, United Kingdom., Paskell J; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Patel JP; Department of Haematological Medicine, King's College Hospital and Institute of Pharmaceutical Science, King's College London, London, United Kingdom., Round C; Comprehensive Clinical Trials Unit, University College London, London, United Kingdom., Sanna G; Louise Coote Lupus Unit, Department of Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Zaidi A; Department of Haematology, Barking, Havering and Redbridge University Hospitals NHS Trust, London, United Kingdom., Werring DJ; Stroke Research Centre, University College London Queen Square Institute of Neurology, London, United Kingdom., Isenberg D; Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom.; Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Cohen H; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Department of Haematology, Cancer Institute, University College London, London, United Kingdom.

Publikováno v: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2024 Jun 05; Vol. 8 (5), pp. 102468. Date of Electronic Publication: 2024 Jun 05 (Print Publication: 2024).

Positive JAK2-V617F leading to diagnosis of Gaucher's disease.

Autor: Appiah-Cubi S, Wilkins BS, Harrison C

Publikováno v: Journal of clinical pathology [J Clin Pathol] 2012 Aug; Vol. 65 (8), pp. 764-5. Date of Electronic Publication: 2012 Mar 29.

A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review.

Autor: Chen Y; Department of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China.; Health Science Center, Ningbo University, Ningbo, 315000, China., Chen T; Department of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China., Fan S; Department of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China.; Health Science Center, Ningbo University, Ningbo, 315000, China., Mu Q; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, China., Ouyang G; Department of Hematology, The First Affiliated Hospital of Ningbo University, No. 59 Liuting Street, Ningbo, 315000, P. R. China. fyyouyangguifang@nbu.edu.cn.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Nov 04. Date of Electronic Publication: 2024 Nov 04.

Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study.

Autor: Du Y; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Wang Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Li Q; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Chang X; Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Shen K; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Zhang H; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Xiao M; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Xing S; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Mar 15; Vol. 154 (6), pp. 969-978. Date of Electronic Publication: 2023 Oct 24.

Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.

Autor: Bastidas‐Mora, Gabriela, Beà, Sílvia, Navarro, Alba, Gine, Eva, Costa, Dolors, Delgado, Julio, Baumann, Tycho, Magnano, Laura, Rivas‐Delgado, Alfredo, Villamor, Neus, Colomer, Dolors, Lopez-Guerra, Mónica, Rozman, María, Balagué, Olga, Martínez, Daniel, Baptista, Maria Joao, Escoda, Lourdes, Alcoceba, Miguel, Blanes, Margarita, Climent, Fina

Publikováno v: British Journal of Haematology; Jan2022, Vol. 196 Issue 1, p146-155, 10p